IL17A and depressive symptom measurement: However, a real-world analysis of patients with psoriasis initiating biologic therapy at or after enrollment in the CorEvitas (formerly Corrona) Psoriasis Patient Registry showed that prevalence rates of history of depression were similar among those initiating brodalumab, IL-12/23 or IL-23 inhibitors, or non-brodalumab IL-17A inhibitors (23%, 26%, and 27%, respectively) [18].